Design
Review
Authors
Loading...
May support cilostazol consideration where bleeding risk predominates; leaves open prospective outcome confirmation.
This review highlights cilostazol's unique mechanisms of action, including PDE3 and adenosine uptake inhibition, positioning it as an antithrombotic agent with a favorable bleeding profile.
Kambayashi et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: